Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 11/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | DHFR | P00374 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL973152 | 0.99 | AOC3 (0.46) | AOC3LMNAGAAALOX12L3MBTL1 | |
| SCHEMBL972553 | 0.86 | EGFR (0.43) | AOC3LMNAGAAALOX12L3MBTL1 | |
| SCHEMBL975090 | 0.84 | AOC3 (0.46) | AOC3L3MBTL1MAOBMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL973480 | 0.84 | AOC3 (0.45) | AOC3L3MBTL1MAOBMAPTSMN1; SMN2 | |
| SCHEMBL970629 | 0.83 | AOC3 (0.69) | AOC3MAOBSMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL973258 | 0.82 | AOC3 (0.67) | AOC3MAOBSMN1; SMN2KMT2A | |
| SCHEMBL974396 | 0.80 | PTPN1 (0.47) | AOC3LMNAGAAALOX12L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3400344 | 0.79 | PTPN1 (0.46) | AOC3LMNAGAAALOX12L3MBTL1 | |
| SCHEMBL973111 | 0.78 | NPC1 (0.62) | AOC3LMNAMAOBMAPTSMN1; SMN2 | |
| SCHEMBL16242229 | 0.78 | L3MBTL1 (0.48) | AOC3LMNAGAAALOX12L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2639229-B9 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2015-08-05 | — | — | EP | claimed |
| EP-2639229-B1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2014-11-26 | — | — | EP | claimed |
| EP-2639229-A2 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-09-18 | — | — | EP | claimed |
| US-8507690-B2 | Thiazole derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2013-08-13 | — | — | US | claimed |
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-01-20 | — | — | US | claimed |
| EP-2639229-B9 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2639229-B1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| EP-2676955-A1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-12-25 | — | — | EP | disclosed |
| EP-2650287-A1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2639229-A2 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-8507690-B2 | Thiazole derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507690-B2 | Thiazole derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, TAS1R1, VAPA | AOC3 438/4885LMNA 1721/4885GAA 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.